Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)

References

• Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71–104.
   PubMed Web of Science ®Google Scholar
• Schweinitz A, Steinmetzer T, Banke IJ, Arlt MJ, Stürzebecher A, Schuster O, Geissler A, Giersiefen H, Zeslawska E, Jacob U, Kruger A, Stürzebecher J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613–33622.
   PubMed Web of Science ®Google Scholar
• Förbs D, Thiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005;27:1061–1070.
   PubMed Web of Science ®Google Scholar
• Steinmetzer T, Schweinitz A, Stürzebecher A, Dönnecke D, Uhland K, Schuster O, Steinmetzer P, Muller F, Friedrich R, Than ME, Bode W, Stürzebecher J. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006;49:4116–4126.
   PubMed Web of Science ®Google Scholar
• Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968–78.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006;66:1411–1429.
   PubMed Web of Science ®Google Scholar
• Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost 2007;5:60–64.
   PubMed Web of Science ®Google Scholar
• Haas S. New anticoagulants - towards the development of an “ideal” anticoagulant. Vasa 2009;38:13–29.
   PubMed Web of Science ®Google Scholar
• Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 2006;7:147–157.
   PubMed Web of Science ®Google Scholar
• Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimisation of antithrombotics: the prodrug principle. Curr Pharm Des 2006;12:73–91.
   PubMed Web of Science ®Google Scholar
• Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 2002;34:565–679.
   PubMed Web of Science ®Google Scholar
• Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, Clement B. Identification of the missing component in the mitochondrial benz-amidoxime prodrug-converting system as a novel molybdenum enzyme. J Biol Chem 2006;281:34796–34802.
   PubMed Web of Science ®Google Scholar
• Grünewald S, Wahl B, Bittner F, Hungeling H, Kanzow S, Kotthaus J, Schwering U, Mendel RR, Clement B. The Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the Activation of N-Hydroxylated Prodrugs. J Med Chem 2008;51:8173–8177.
   PubMedGoogle Scholar
• Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667–715.
   PubMed Web of Science ®Google Scholar
• Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Muller M, Knopp D, Levet-Trafit B, Lipari M, Modi N, Muller M, Refino C, Schmitt M, Schonholzer P, Weiss S, Steiner B. Orally active fibrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996;39:3139–3147.
   PubMed Web of Science ®Google Scholar
• Stürzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikström P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999;9:3147–3152.
   PubMed Web of Science ®Google Scholar
• Stürzebecher A, Dönnecke D, Schweinitz A, Schuster O, Steinmetzer P, Stürzebecher U, Kotthaus J, Clement B, Stürzebecher J, Steinmetzer T. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2. ChemMedChem 2007;2:1043–1053.
   PubMed Web of Science ®Google Scholar
• Schweinitz A, Dönnecke D, Ludwig A, Steinmetzer P, Schulze A, Kotthaus J, Wein S, Clement B, Steinmetzer T. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors. Bioorg Med Chem Lett 2009;19:1960–1965.
   PubMed Web of Science ®Google Scholar
• Krueger P. Über Abkömmlinge des Benzenylamidoxims. Ber Dtsch Chem Ges 1885;18:1055–1060.
   Google Scholar
• Gummow B, du Preez JL, Swan GE. Paired-ion extraction and high-performance liquid chromatographic determination of diminazene in cattle plasma: a modified method. Onderstepoort J Vet Res 1995;62:1–4.
   PubMedGoogle Scholar
• Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645–651.
   PubMed Web of Science ®Google Scholar
• Clement B, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino)iminomethyl]benzoyl]amino]-1-oxopropyl]-4- piperidinyl]oxy]-acetic acid). Drug Metab Dispos 2005;33:1740–1747.
   PubMed Web of Science ®Google Scholar
• Clement B, Bürenheide A, Rieckert W, Schwarz J. Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem 2006;1:1260–7.
   PubMed Web of Science ®Google Scholar
• Albert A, Goldacre R, Phillips J. The strength of heterocyclic bases. J Chem Soc 1948;2240–2249.
   Web of Science ®Google Scholar
• Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nystrom JE, Eriksson U, Bredberg U, Teger-Nilsson AC. A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004;3:649–659.
   PubMed Web of Science ®Google Scholar